While the biochemical rationale for the effect of PD-1/PD-L1 in sorafenib-treated HCC has been at least partially described, the role of this important immune checkpoint is unclear in patients who receive adjuvant sorafenib. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.